Skip to main content
SpringerLink
Log in

Endothelin and Cardiovascular Function

  • Chapter
Endocrinology of Cardiovascular Function

Part of the book series: Endocrine Updates ((ENDO,volume 1))

Abstract

The endothelins (ETs) are a family of three isopeptides, endothelin-1 (ET-1), ET-2 and ET-3, each of which is encoded in the human genome. Since their discovery (1), there have been a prodigious number of studies describing their potential role in physiological and pathophysiological processes (for review see (2)). Much of the early evidence implicating the ETs in disease was indirect, linking elevations in endogenous ET levels with pathophysiology. More compelling data based upon the use of specific receptor antagonists in clinical studies are now available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 332: 411–415, 1988

    Article  CAS  Google Scholar 

  2. Ohlstein EH, Douglas SA, Brooks DP, Hay DWP, Feuerstein GZ, Ruffolo RR, JR. Functions mediated by peripheral endothelin receptors, in Endothelin Receptors: From the Gene to the Human, edited by Ruffolo RR, JR. CRC Press, 1995, p. 109

    Google Scholar 

  3. Arai H, Hori S, Aramori I, Ohkubo H, Nakanish S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature London 348: 730–732, 1990

    Article  PubMed  CAS  Google Scholar 

  4. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki TE: Cloning of a cDNA encoding a nonisopeptide-selective subtype of an endothelin receptor. Nature London 348: 732–735, 1990

    Article  PubMed  CAS  Google Scholar 

  5. Denucci G, Thomas R, D’Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane Jr: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85: 9797–9800, 1988

    Article  CAS  Google Scholar 

  6. Warner TD, Allcock GH, Corder R, Vane JR: Use of the endothelin antagonists BQ123 and PD142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 110: 777–782, 1993

    Article  PubMed  CAS  Google Scholar 

  7. Douglas SA, Beck GR, Jr., Lelliott JD, Ohlstein EH: Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br J Pharmacol 114: 1529–1540, 1995

    Article  PubMed  CAS  Google Scholar 

  8. Webb ML, Meek TD: Inhibitors of endothelin. Med Res Rev 17: 17–67, 1997

    Article  PubMed  CAS  Google Scholar 

  9. Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo RR, JR. Endothelin receptors: receptor classification, novel receptor antagonists and potential therapeutic targets. Med Res Rev 16: 365–390, 1996

    Article  PubMed  CAS  Google Scholar 

  10. Peishoff Ce, Lago Ma, Ohlstein Eh, Elliott Jd: Endothelin receptor antagonists. Cur Pharm Design 1: 425–440, 1996

    Google Scholar 

  11. Vierhapper H, Wagner O, Nowotny P, Waldhausl W: Effect of endothelin-1 in man. Circulation 81: 1415–1418, 1990

    Article  PubMed  CAS  Google Scholar 

  12. Sorensen SS, Madsen JK, Pedersen EB: Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 266: F411–F418, 1994

    PubMed  CAS  Google Scholar 

  13. Rabelink TJ, Kaasiager KAH, Boer P, Stroes EG, Braam B, Koomans HA: Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 46: 376–381, 1994

    Article  PubMed  CAS  Google Scholar 

  14. Wilkins FC, JR., Alberola A, Mizelle HL, Opgenorth TJ, Granger JP: Chronic pathophysiological circulating endothelin levels produce hypertension in conscious dogs. J Cardiovasc Pharmacol 22: S325–S327, 1993

    Article  PubMed  CAS  Google Scholar 

  15. Niranjan V, Telemaque S, Dewit D, Gerard RD, Yanagisawa M: Systemic hypertension induced by hepatic overexpression of human prepro-endothelin-1 in rats. J Clin Invest 98: 2364–2372, 1996

    Article  PubMed  CAS  Google Scholar 

  16. Jorkasky DK, Hay DWP, Freed MI: The role of endothelin in human disease: implications and potential therapeutic intervention, in Endothelin Receptors: From the Gene to the Human, edited by Ruffolo RR, JR. CRC Press, 1995, p. 215

    Google Scholar 

  17. Wong M, Jeng AY: Parallel increases in cardiac endothelin and blood pressure of spontaneously hypertensive rats. Pharmacologist 31: 3741989

    Google Scholar 

  18. Fujita K, Matsumura Y, Miyazaki Y, Hashimoto N, Takaoka M, Morimoto S: ETA receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats. Life Sci 58: PL1-PL7, 1996

    Google Scholar 

  19. Takada K, Matsumura Y, Dohmen S, Mitsutomi N, Takaoka M, Morimoto S: Endothelin-1 secretion from cultured vascular endothelial cells of DOCA-salt hypertensive rats. Life Sci 59: PL111–PL116, 1996

    Google Scholar 

  20. Hocher B, Rohmeiss P, Zart R, Diekmann F, Vogt V, Metz D, Fakhury M, Gretz N, Bauer C, Koppenhagen K, Neumayer HH, Distler A: Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 31: 499–510, 1996

    PubMed  CAS  Google Scholar 

  21. Schiffrin EL, Lariviere R, Touyz RM: ETA and ETB receptors on vascular smooth muscle cells from mesenteric vessels of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 22: S193–S194, 1995

    Article  CAS  Google Scholar 

  22. Hiraoka J, Arai H, Yoshimasa T, Takaya K, Miyamoto Y, Yamashita J, Suga S, Ogawa Y, Shirakami G, Itoh H: Augmented expression of the endothelin-A receptor gene in cultured mesangial cells from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 22: S191–S192, 1995

    Article  CAS  Google Scholar 

  23. Gellai M, Fletcher T, Pullen M, Nambi P: Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol 271: R254–R26l, 1996

    PubMed  CAS  Google Scholar 

  24. Mcmahon EG, Palomo MA, Moore WM: Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. Cardiovasc Pharmacol 17: S29–S33, 1991

    Article  CAS  Google Scholar 

  25. Nishikibe M, Tsuchida S, Okada M, Fukuroda R, Shimamoto K, YANO M: Antihypertensive effect of a newly synthesized endothelin antagonist, BQ123, in a genetic hypertensive model. Life Sci 52: 717–724, 1993

    Article  PubMed  CAS  Google Scholar 

  26. Ohlstein EH, Douglas SA, Ezekiel M, Gellai M: Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 22: S321–S324, 1993

    Article  PubMed  CAS  Google Scholar 

  27. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, Cousins RD, Gao A, Frazee JS, Peishofe CE, Bean JW, Eggleston DS, Elshourbagy NA, Kumar C, Lee JA, Brooks DP, Ruffolo RR, JR., Feuerstein GZ, Weinstock J, Gleason JG, Elliott JD: SB 209670, rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 9: 8052–8056, 1994

    Article  Google Scholar 

  28. Douglas SA, Gellai M, Ezekiel M, Ohlstein EH: BQ-123, selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens 12: 561–567, 1994

    Article  PubMed  CAS  Google Scholar 

  29. Bird JE, Moreland S, Waldron TL, Powell JR: Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 25: 1191–1195, 1995

    Article  PubMed  CAS  Google Scholar 

  30. Bazil MK, Lappe RW, Webb RL: Pharmacologic characterization of an endothelin A (ETA) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 20: 940–948, 1992

    Article  PubMed  CAS  Google Scholar 

  31. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732–736, 1995

    Article  PubMed  CAS  Google Scholar 

  32. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852–854, 1994

    Article  PubMed  CAS  Google Scholar 

  33. Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, Webb DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93: 1860–1870, 1996

    Article  PubMed  CAS  Google Scholar 

  34. Freed MI, Thompson KA, Wilson DE, Ohlstein EH, Dennis M, Jorkasky DK: Effects of SB 217242, a non-selective endothelin (ET-A and ET-B) receptor antagonist, in healthy humans. J Am Soc Nephrol 7: 15611996

    Google Scholar 

  35. Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, Yushak M, Miller M, Packer M: Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 131: 337–341, 1996

    Article  PubMed  CAS  Google Scholar 

  36. Hemsen A, Franco-Cereceda A, Matran R, Rudehill A, Lundberg JM: Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur J Pharmacol 191: 319–328, 1990

    Article  PubMed  CAS  Google Scholar 

  37. Henry PJ, Rigby PJ, Self GJ, Preuss JM, Goldie RG: Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle. Br J Pharmacol 100: 786–792, 1990

    Article  PubMed  CAS  Google Scholar 

  38. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Eng J Med 328: 1732–1739, 1993

    Article  PubMed  CAS  Google Scholar 

  39. Stelzner TJ, O’Brien RF, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, Mcmurty IF, Fisher JH: Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 262: L614–L618, 1992

    PubMed  CAS  Google Scholar 

  40. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, Sugishita Y: Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J Am Coll Cardiol 28: 1580–1588, 1996

    Article  PubMed  CAS  Google Scholar 

  41. Maclean MR, Mcculloch KM, Baird M: Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6c and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol 26: 822–830, 1995

    Article  PubMed  CAS  Google Scholar 

  42. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73: 887–897, 1993

    Article  PubMed  CAS  Google Scholar 

  43. Bonvallet ST, Zamora MR, Hasunuma K, Sato K, Hanasato N, Anderson D, Stelzner TJ: BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 266: H1327–H1331, 1994

    PubMed  CAS  Google Scholar 

  44. Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Hay DWP: Nonpeptide endothelin receptor antagonists. X. Inhibition of endothelin-1-and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist SB 217242. J Pharmacol Exp Ther 283: 1130–1137, 1997

    PubMed  CAS  Google Scholar 

  45. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhausl W: Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 222: 277–282, 1992

    Article  Google Scholar 

  46. Wei CM, Lerman A, Rodeheffer RJ, Mcgregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC, JR. Endothelin in human congestive heart failure. Circulation 89: 1580–1586, 1994

    Article  PubMed  CAS  Google Scholar 

  47. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27: 633–641, 1996

    Article  PubMed  CAS  Google Scholar 

  48. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K: Plasma endothelin determinations as a prognostic indication of one year mortality after acute myocardial infarction. Circulation 89: 1573–1579, 1994

    Article  PubMed  CAS  Google Scholar 

  49. Cavero PG, Miller WL, Heublein DM, Margulies KB, Burnett JC: Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 259: F312–F317, 1990

    PubMed  CAS  Google Scholar 

  50. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K: Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett 332: 31–34, 1993

    Article  PubMed  CAS  Google Scholar 

  51. Miyauchi T, Sakai S, Ihara M, Kasuya Y, Yamaguchi I, Goto K, Sugishita Y: Increased endothelin-1 binding sites in the cardiac membranes in rats with chronic heart failure. J Cardiovasc Pharmacol 26: S448–S451, 1995

    PubMed  CAS  Google Scholar 

  52. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y: Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271: 3221–3228, 1996

    Article  PubMed  CAS  Google Scholar 

  53. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y, Marumo F: Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89: 2198–2203, 1994

    Article  PubMed  CAS  Google Scholar 

  54. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozelm, Clozel JP: Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 90: 2510–2518, 1994

    Article  PubMed  CAS  Google Scholar 

  55. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353–355, 1996

    Article  PubMed  CAS  Google Scholar 

  56. Shimoyama H, Sabbah HN, Borzak S, Tanimura M, Shevlyagin S, Scicli G, Goldstein S: Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 94: 779–784, 1996

    Article  PubMed  CAS  Google Scholar 

  57. Davidson NC, Coutie WJ, Webb DJ, Struthers AD: Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 75: 576–581, 1996

    Article  PubMed  CAS  Google Scholar 

  58. Tohmo H, Karanko M, Klossner J, Scheinin M, Viinamaki O, Neuvonen P, Ruskoaha H: Enalaprilat decreases plasma endothelin and atrial natriuretic peptide levels and preload in patients with left ventricular dysfunction after cardiac surgery. J Cardiothorac Vase Anesth 11: 585–590, 1997

    Article  CAS  Google Scholar 

  59. Grenier O, Pousset F, Isnard R, Kalotka H, Carayon A, Maistre G, Lechat P, Guerot C, Thomas D, Komajda M: Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure. Cardiovasc Drugs Ther 10: 561–565, 1996

    Article  PubMed  CAS  Google Scholar 

  60. Ohlstein EH, Arleth AJ, Storer B, Romanic AM: Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cell. J Mol Cell Cardiol 30: 167–173, 1998

    Article  PubMed  CAS  Google Scholar 

  61. Sutsch G, Bertel O, Kiowski W: Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 10: 717–725, 1997

    Article  PubMed  CAS  Google Scholar 

  62. Kon V, Yoshioka T, Fogo A, Ichikawa I: Glomerular actions of ET in vivo. J Clin Invest 83: 1762–1767, 1989

    Article  PubMed  CAS  Google Scholar 

  63. Simonson MS, Dunn MJ: Endothelin peptides: a possible role in glomerular inflammation. Lab Invest 64: 1–41, 1991

    PubMed  CAS  Google Scholar 

  64. Kon V, Badr KF: Biological actions and pathophysiologic significance of ET in the kidney. Kidney Int 40: 11991

    Google Scholar 

  65. Kohan DE: Endothelins in the kidney: physiology and pathophysiology. Am J Kidney 22: 4931993

    CAS  Google Scholar 

  66. Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F: Plasma ET levels in patients with acute renal failure. Eur J Med 32: 11271989

    Google Scholar 

  67. Sandok EK, Lerman A, Stingo AJ, Perrella MA, Gloviczki P, Burnett JC, JR. Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor. J Am Soc Nephrol 3: 196–202, 1992

    Google Scholar 

  68. Shibouta Y, Suzuki N, Shino A, Matsumoto H, Terashita Z, Kondo K, Nishikawa K: Pathophysiological role of endothelin in acute renal failure. Life Sci 46: 1611–1618, 1990

    Article  PubMed  CAS  Google Scholar 

  69. Nambi P, Pullen M, Jugus M, Gellai M: Rat kidney endothelin receptors in ischemia-induced acute renal failure. J Pharmacol Exp Ther 264: 345–348, 1993

    Google Scholar 

  70. Wilkes BM, Pearl AR, Mento PF, Maita ME, Macica CM, Girardi EP: Glomerular ET receptors during initiation and maintenance of ischemic acute renal failure in rats. Am J Physiol 260: F110–F118, 1991

    PubMed  CAS  Google Scholar 

  71. LOPEZ-Farre A, Gomez-Garre D, Bernabeu F, Lopez-NOVOA J: A role for ET in the maintenance of post-ischemic renal failure in the rat. J Physiol 444: 513–522, 1991

    PubMed  CAS  Google Scholar 

  72. Gellai M, Jugus M, Fletcher T, Dewolf R, Nambi P: Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat. J Clin Invest 93: 900–906, 1994

    Article  PubMed  CAS  Google Scholar 

  73. Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, Ishikawa K, Watanabe K, Nishikibe M, Ikemoto F, Ikemoto F: Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 221: 77–83, 1992

    Article  PubMed  CAS  Google Scholar 

  74. Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW: Effect of an ET receptor antagonist on ischemic acute renal failure. Am J Physiol 266: F135–F138, 1994

    PubMed  CAS  Google Scholar 

  75. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP: Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 275: 200–206, 1995

    PubMed  CAS  Google Scholar 

  76. Clozel M, Breu V, Burri K, Cassal J, Fischli W, Gray GA, Hirth G, Loffler B, Muller M, Neidhart W, Ramuz H: Pathophysiological role of ET revealed by the first orally active ET receptor antagonist. Nature 365: 759–761, 1993

    Article  PubMed  CAS  Google Scholar 

  77. Kusumoto K, Kubo K, Kandori H, Kitayoshi T, Sato S, Wakimasu M, Watanabe T, Fujino M: Effects of a new endothelin antagonist, TAK-044, on post-ischemic acute renal failure in rats. Life Sci 55: 301–310, 1996

    Article  Google Scholar 

  78. Lanese DM, Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 91: 2144–2149, 1993

    Article  PubMed  CAS  Google Scholar 

  79. Brooks DP, Contino LC: Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist, SB 209670. Eur J Pharmacol 294: 571–576, 1995

    Article  PubMed  CAS  Google Scholar 

  80. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of ET in cyclosporine-induced glomerular dysfunction. Kidneylnt 37: 1487–1491, 1990

    CAS  Google Scholar 

  81. Bloom ITM, Bentley FR, Garrison RN: Acute cyclosporine-induced renal vasoconstriction is mediated by ET-1. Surgery 114: 480–488, 1993

    PubMed  CAS  Google Scholar 

  82. Perico N, Dadan J, Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1: 76–83, 1990

    PubMed  CAS  Google Scholar 

  83. Fogo A, Hellings SE, Inagami T, Kon V: Endothelin receptor antagonism is protective in in vitro acute cyclosporine toxicity. Kidney Int 42: 770–774, 1992

    Article  PubMed  CAS  Google Scholar 

  84. Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R: Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 26: 932–936, 1995

    Article  PubMed  CAS  Google Scholar 

  85. Koyama H, Nishizawa Y, Morii EH, Tabata T, Inoue T, Yamaji T: Plasma endothelin levels in patients with uremia. Lancet 1: 991–992, 1989

    Article  PubMed  CAS  Google Scholar 

  86. Predel HG, Meyer-Lehnert A, Backer A, Stelkens H, Kramer HJ: Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Effects of ergometric exercise and acute saline loading. Life Sci 47: 1837–1843, 1990

    Article  PubMed  CAS  Google Scholar 

  87. Brooks DP, Contino LC, Storer B, Ohlstein EH: Increased ET excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 104: 987–989, 1991

    Article  PubMed  CAS  Google Scholar 

  88. Benigni A, Perico N, Ladny JR, Imberti O, Bellizzi L, Remuzzi G: Increased urinary excretion of ET-1 and its precursor, big ET-1, in rats chronically treated with cyclosporine. Transplantation 52: 175–177, 1991

    Article  PubMed  CAS  Google Scholar 

  89. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G: Renal ET gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43: 354–358, 1993

    Article  PubMed  CAS  Google Scholar 

  90. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G: A specific ET subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44: 440–444, 1993

    Article  PubMed  CAS  Google Scholar 

  91. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin-A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481–489, 1995

    Article  PubMed  CAS  Google Scholar 

  92. Benigni A, Zola C, Corna D, Orisio S, Facchinetti D, Benati L, Remuzzi G: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27: 416–423, 1996

    Article  PubMed  CAS  Google Scholar 

  93. Nabokov A, Amann K, Wagner J, Gehlen F, Munter K, Ritz E: Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 11: 514–520, 1996

    Article  PubMed  CAS  Google Scholar 

  94. Pollock DM, Polakowski JS: ETA receptor blockade prevents hypertension associated with exogenous ET-1 but not renal mass reduction in the rat. J Am Soc Nephrol 8: 1054–1060, 1997

    PubMed  CAS  Google Scholar 

  95. MARTIN-Nizard F, Houssaini HS, Lestavel-Delattre S, Duriez P, Fruchart J: Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett 293: 127–130, 1991

    Article  PubMed  CAS  Google Scholar 

  96. Ohlstein EH, Douglas SA: Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Develop Res 29: 108–128, 1993

    Article  CAS  Google Scholar 

  97. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC: Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol 28: 14–19, 1996

    Article  PubMed  CAS  Google Scholar 

  98. Ihling C, Gobel HR, Lippoldt A, Wessels S, Paul M, Schaefer HE, Zeiher AM: Endothelin-1-like immunoreactivity in human atherosclerotic coronary tissue: a detailed analysis of the cellular distribution of endothelin-1. J Pathol 179: 303–308, 1996

    Article  PubMed  CAS  Google Scholar 

  99. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Polizzi G, Tamburino G: Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Internatl Angiol 15: 240–244, 1996

    CAS  Google Scholar 

  100. Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, Burnett JC, JR. Circulating and tissue endothelin immunoreactivity in hypercholesterolemia pigs. Circulation 88: 2923–2928, 1993

    Article  PubMed  CAS  Google Scholar 

  101. Azuma H, Hamasaki H, Niimi Y, Terada T, Matsubara O: Role of endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries. Am J Physiol 267: H2259–H2267, 1994

    PubMed  CAS  Google Scholar 

  102. Wang X, Douglas SA, Ohlstein EH: The use of quantitative RT-PCR to demonstrate the increased expression of endothelin-related mRNAs following angioplasty-induced neointima formation in the rat. Circ Res 78: 322–328, 1996

    Article  PubMed  CAS  Google Scholar 

  103. Lopez JAG, Armstrong ML, Piegors DJ, Heistad DD: Vascular responses to endothelin-1 in atherosclerotic primates. Artherosclerosis 10: 1113–1118, 1990

    CAS  Google Scholar 

  104. Prat L, Carrio I, Roca M, Riambau V, Berne L, Estorch M, Ferrer I, Garcia C: Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-l accumulation in experimental arterial wall injury. Eur J Nucl Med 20: 1141–1145, 1993

    PubMed  CAS  Google Scholar 

  105. Dashwood M, Barker SGE, Muddle JR, Yacoub MH, Martin JF: [125I] endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimal hyperplasia and atherosclerosis. J Cardiovasc Pharmacol 22: S343–S347, 1993

    Article  PubMed  CAS  Google Scholar 

  106. Dashwood MR, Allen SP, Luu TN, Muddle JR: The effect of the ETA receptor antagonist, FR 139317, on [125I] ET-1 binding to the atherosclerotic human coronary artery. Br J Pharmacol 112: 386–389, 1994

    Article  PubMed  CAS  Google Scholar 

  107. Kurata C, Callahan RJ, Molea N, Wilkinson R, Fischman AJ, Strauss HW: Localization of [125I] endothelin-1 in injured aorta of rabbits. Eur J Pharmacol 293: 109–114, 1995

    Article  PubMed  CAS  Google Scholar 

  108. Bacon CR, Cary NR, Davenport AP: Distribution of endothelin receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 26: S439–S441, 1995

    PubMed  CAS  Google Scholar 

  109. Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, Ohlstein EH: A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res 75: 190–197, 1994

    Article  PubMed  CAS  Google Scholar 

  110. Trachtenberg JD, Sun S, Choi ET, Callow AD, Ryan US: Effect of endothelin-1 infusion on the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol 22: S355–S359, 1993

    Article  PubMed  CAS  Google Scholar 

  111. Ferrer P, Valentine M, Jenkins-West T, Weber H, Goller NL, Durham SK, Molloy CJ, Moreland S: Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J Cardiovasc Pharmacol 26: 908–915, 1995

    Article  PubMed  CAS  Google Scholar 

  112. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, Valentine M, Barton D, Durham SK: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 146: 819–826, 1995

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Cardiovascular and Renal Pharmacology and Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA, 19406-0939, USA

    Eliot H. Ohlstein, John D. Elliott & David P. Brooks

Authors
  1. Eliot H. Ohlstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David P. Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. DVA Medical Center and University of California, Irvine, USA

    Ellis R. Levin M.D.

  2. City of Hope Medical Center, Duarte, California, USA

    Jerry L. Nadler M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ohlstein, E.H., Elliott, J.D., Brooks, D.P. (1998). Endothelin and Cardiovascular Function. In: Levin, E.R., Nadler, J.L. (eds) Endocrinology of Cardiovascular Function. Endocrine Updates, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5569-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5569-8_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7547-0

  • Online ISBN: 978-1-4615-5569-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation